logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Aligos Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 38


Forward Citations = 35

Loading Chart...
Loading Chart...

41 inventors (with patents filed for the assignee):

goldMedal Leonid Beigelman (20 out of 227 patents)

silverMedal Pierre Jean-Marie Bernard Raboisson (17 out of 178 patents)

bronzeMedal Koen Vandyck (13 out of 46 patents)

4.  Jerome Deval (12 out of 30 patents)

5.  David Craig McGowan (11 out of 62 patents)

6.  Antitsa Dimitrova Stoycheva (11 out of 21 patents)

7.  Sandrine Vendeville (10 out of 11 patents)

8.  Pierre Jean-Marie Bernard Raboisson (7 out of 9 patents)

9.  Yannick Debing (6 out of 6 patents)

10.  David Bernard Smith (5 out of 89 patents)

11.  Vivek Kumar Rajwanshi (5 out of 19 patents)

12.  Jin Hong (5 out of 10 patents)

13.  Tongfei Wu (5 out of 28 patents)

14.  Dorothée Alice Marie-Eve Bardiot (5 out of 25 patents)

15.  Rajendra K Pandey (5 out of 8 patents)


Core Competencies:
Pyridazinone
Anti-Viral Compounds
PD-L1
Modified Nucleic Acids
Bicyclic Compounds
THR-β Modulators
Heterocyclic Compounds
Tricyclic Compounds
Oligonucleotides
Imidazo[1,5-a]Pyrazines
Oxindoles
Sulfonamides

38 patents:

1. 12760018 - BICYCLIC COMPOUNDS (2026-10-13),
2. 12630538 - Anti-viral compounds (2026-05-19),
3. 12630537 - Pyridazinone and methods of use thereof (2026-05-19),
4. 12534450 - Methods and compositions for targeting PD-L1 (2026-01-27),
5. 12454691 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2025-10-28),
6. 12428427 - Methods and compositions for targeting PD-L1 (2025-09-30),
7. 12384779 - Bicyclic compounds (2025-08-12),
8. 12252481 - Anti-viral compounds (2025-03-18),
9. 12180192 - Modulators of THR-β and methods of use thereof (2024-12-31),
10. 12129469 - Modified short interfering nucleic acid (siNA) molecules and uses thereof (2024-10-29),
11. 12065428 - Anti-viral compounds (2024-08-20),
12. 12018015 - Methods and compositions for targeting PD-L1 (2024-06-25),
13. 11957683 - Bicyclic compounds (2024-04-16),
14. 11952374 - Bicyclic compounds (2024-04-09),
15. 11952365 - Anti-viral compounds (2024-04-09),
Company Overview
Aligos Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for viral infections and liver diseases. The company specializes in advancing novel drug candidates that target unmet medical needs, particularly in the areas of hepatitis B and other chronic viral infections. Aligos leverages its proprietary technology platforms to create therapeutics aimed at improving patient outcomes and addressing significant health challenges in the field of infectious diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Aligos Therapeutics, Inc. USPTO Patent Assignee Logo
38 Patents

#39 in South San Francisco, CA

#2,137 in California

#9,043 in US

#17,876 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Aligos Therapeutics, Inc.

Forward Citations = 35

41 inventors:

goldMedal Leonid Beigelman (20 out of 227 patents)

silverMedal Pierre Jean-Marie Bernard Raboisson (17 out of 178 patents)

bronzeMedal Koen Vandyck (13 out of 46 patents)

4.  Jerome Deval (12 out of 30 patents)

5.  David Craig McGowan (11 out of 62 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aligos Therapeutics, Inc.. Retrieved from https://idiyas.com/company/aligos-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…